{'fraction_non_alphanumeric': 0.0334835801674179, 'fraction_numerical': 0.04056664520283323, 'mean_word_length': 4.395833333333333, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Immunogenicity of the Heberbiovac-HB vaccine in the physically and mentally handicapped].

The recombinant DNA Heberbiovac-HB vaccine against hepatitis B was applied to 2 groups of children at 2 homes for the physically and mental disabled at doses of 10 and 5 micrograms with the scheme 0, 1 and 6 months to study its immunogenicity, which was evaluated at 2, 7 and 12 months after the first dose was administered. On the 60th day it was obtained 80.9% of seroprotection in children who received 10 micrograms, whereas in the group that was vaccinated with 5 micrograms 65.0% of seroprotection was attained and there were no significant differences between the groups. 100% of seroprotection (> or = 10 UI/L) was obtained in the 2 vaccinated groups when the immune response was measured 1 month after the third dose was applied. A year later, seroprotection was 100% for the 2 groups of children. The geometrical mean of the antibody titres (TMG) reached levels above 10 UI/L, which is the minimum protector, in the 2 study groups 30 days after the second dose. A month after the third dose, the TMG attained values of 527.7 UI/L in the group of 10 micrograms and of 324.7 UI/L in that of 5 micrograms. No remarkable differences were found between the groups (p < 0.05). Finally, 365 days later, the TMG descended to 139.7 UI/L and 57.3 UI/L in the same groups, respectively. It was demonstrated the high immunogenic power of this vaccine, which makes it recommendable for protecting the physical and mentally disabled children from hepatitis B virus.